Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Sunlenca Trogarzo PA | OpenPa…
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Anti-Retroviral Agents: Sunlenca (lenacapavir) and Trogarzo (ibalizumab-uiyk)

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization criteria for Sunlenca and Trogarzo under the MassHealth medical benefit for adults with heavily treatment-experienced, multidrug-resistant HIV-1.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicySunlenca and Trogarzo Coverage Criteria
    Policy CodePolicy N/A
    Change TypeRevised — Trogarzo step-through requirement added
    Effective DateJanuary 4, 2027
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionDocument an inadequate response or adverse reaction to Rukobia or Sunlenca, or contraindications to both, when requesting Trogarzo.
    SourceLink
    POLICY UPDATE CHANGES

    Trogarzo coverage now requires inadequate response or an adverse reaction to Rukobia or Sunlenca, or contraindication to both drugs.

    2Antiretroviral drugs covered
    18+

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Minimum age
    >200Detectable viremia example
    12 monthsAuthorization period
    3Resistance classes for Trogarzo

    General Coverage Criteria

    New-member transition

    For members new to the plan with coverage effective for 90 days or less, submit documentation of current treatment with the requested drug.

    New-member transition documentation: Member has coverage effective for 90 days or less, and medical records document current treatment with the requested drug. Treatment obtained as samples or through a manufacturer's patient assistance program does not meet this requirement.coverage effective date <= 90 days

    Applies to members new to the plan.

    Sunlenca initial therapy

    Sunlenca may be authorized when all of the following are met.

    • Eligibility and treatment criteria

      • Member has a diagnosis of HIV-1 infection.
      • Member is at least 18 years of age.>= 18 years
      • Member has ongoing detectable viremia.e.g., >200 copies/mL
      • Member is antiretroviral experienced with documented historical or baseline resistance, intolerability, and/or contraindication to an antiretroviral.

        The documented history must concern an antiretroviral that is not part of the current regimen.

      • Member is failing the current antiretroviral regimen due to resistance, intolerance, or safety considerations.

        The documented resistance, adverse reaction, or safety concern must concern the current antiretroviral regimen.

      • Sunlenca will be used as combination antiretroviral therapy with at least one other antiretroviral.
      • Member will receive appropriate dosing.

    Trogarzo initial therapy

    Trogarzo may be authorized when all of the following are met.

    • Eligibility and treatment criteria

      • Member has a diagnosis of HIV-1 infection.
      • Member is at least 18 years of age.>= 18 years
      • Member has ongoing detectable viremia.e.g., >200 copies/mL
      • Member has resistance to one antiretroviral medication from each of the NRTI, NNRTI, and PI classes.

        Combination agents count toward the three classes.

    Continuation therapy

    Continuation therapy is supported by prescriber resubmission.

    Continuation therapy: Resubmission by the prescriber will infer a positive response to therapy.

    Initial approvals and reauthorizations are issued for 12 months.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Sunlenca (lenacapavir) and Trogarzo (ibalizumab-uiyk) under the MassHealth medical benefit. These medications are also available under the pharmacy benefit; consult the MassHealth Drug List for pharmacy coverage and criteria.

    • Medical benefit PA phone: 833-895-2611; fax: 888-656-6671.
    • Pharmacy benefit phone: 800-711-4555; fax: 844-403-1029.
    Billing Rule

    12-Month Authorization Period

    Initial approvals and reauthorizations for Sunlenca and Trogarzo are limited to a 12-month authorization period.

    • Submit a reauthorization request before the current 12-month approval expires.

    Policy Background

    Sunlenca (lenacapavir) and Trogarzo (ibalizumab-uiyk) are used in combination with other antiretroviral agents for heavily treatment-experienced adults with multidrug-resistant HIV-1. Sunlenca is intended for patients whose current antiretroviral regimen is failing because of resistance, intolerance, or safety considerations; Trogarzo is intended for patients with multidrug-resistant HIV-1 whose current regimen is failing.

    Clinical Definitions

    Antiretroviral resistance, intolerance, or contraindication history
    DefinitionDocumented history of resistance, adverse reaction, or contraindication to an antiretroviral.
    Documentation scopeThe history must concern an antiretroviral that is not part of the current regimen.
    TimingThe resistance, intolerance, or contraindication may be historical or baseline.
    Failure of current antiretroviral regimen
    DefinitionDocumented resistance, adverse reaction, or safety concern with the current antiretroviral regimen.
    Qualifying concernsResistance, intolerance or adverse reaction, or safety considerations affecting the current regimen.

    Initial Therapy Requirements

    Sunlenca initial therapy

    Sunlenca authorization requires all of the following criteria.

    Sunlenca eligibility

    • Member has a diagnosis of HIV-1 infection.
    • Member is at least 18 years of age.>= 18 years
    • Member has ongoing detectable viremia.e.g., >200 copies/mL
    • Member is antiretroviral experienced with documented historical or baseline resistance, intolerability, and/or contraindication to an antiretroviral.

    Continuation of Therapy

    Continuation of therapy

    Continuation of therapy is supported by prescriber resubmission.

    Positive response: Resubmission by the prescriber will infer a positive response to therapy.

    Trogarzo Step-Therapy Requirement

    StepMedication(s)Requirement
    1Rukobia (fostemsavir) or Sunlenca (lenacapavir)Inadequate response or adverse reaction to one of the medications, or a contraindication to both medications.
    Policy Summary
    PayerMass General Brigham Health Plan
    PolicySunlenca and Trogarzo Coverage Criteria
    Policy CodePolicy N/A
    Change TypeRevised — Trogarzo step-through requirement added
    Effective DateJanuary 4, 2027
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionDocument an inadequate response or adverse reaction to Rukobia or Sunlenca, or contraindications to both, when requesting Trogarzo.
    SourceLink
    On This Page
    General Coverage CriteriaAuthorization and Documentation RequirementsPolicy BackgroundClinical DefinitionsInitial Therapy RequirementsContinuation of TherapyTrogarzo Step-Therapy Requirement
    Trogarzo will be used as combination antiretroviral therapy with at least one other antiretroviral.
  1. Member will receive appropriate dosing.
  2. Rukobia/Sunlenca requirement

    • ONE of

      • Member has an inadequate response to one of Rukobia (fostemsavir) or Sunlenca (lenacapavir).one drug
      • Member has an adverse reaction to one of Rukobia (fostemsavir) or Sunlenca (lenacapavir).one drug
    • Both drugs: Member has a contraindication to both Rukobia (fostemsavir) and Sunlenca (lenacapavir).both drugs
  3. Step Therapy

    Trogarzo Step-Through Requirement

    For Trogarzo, document an inadequate response or adverse reaction to one of Rukobia or Sunlenca, or a contraindication to both Rukobia and Sunlenca.

    • Rukobia (fostemsavir) and Sunlenca (lenacapavir) are the required step-through products.
    • The step-through requirement is separate from documenting resistance to antiretroviral medications in each of the three specified classes.
    Documentation Required

    New-Member Transition Records

    For a member whose coverage effective date is less than or equal to 90 days, submit medical records documenting that the member is currently receiving treatment with the requested drug.

    • Do not use samples or manufacturer patient-assistance-program supply as evidence of current treatment.
    • Absent current-treatment records may place the request at risk for denial.
    Documentation Required

    Clinical Eligibility Documentation

    Document the clinical eligibility requirements for the requested product. Both products require HIV-1 infection, age 18 years or older, ongoing detectable viremia (for example, >200 copies/mL), combination antiretroviral therapy with at least one other antiretroviral, and appropriate dosing.

    • For Sunlenca, document antiretroviral experience with historical or baseline resistance, intolerance, and/or contraindication to an antiretroviral, plus failure of the current regimen because of resistance, intolerance, or safety concerns.
    • For Trogarzo, document resistance to one antiretroviral from each of the NRTI, NNRTI, and PI classes, including combination agents.
    • For Sunlenca, the resistance, adverse-reaction, or contraindication history must involve an antiretroviral that is not part of the current regimen; document the relevant history and current-regimen concern.
    • Include the applicable laboratory results, treatment history, resistance information, adverse reactions, contraindications, and dosing plan in the authorization request.
    Documentation Required

    Combination-Therapy Rationale

    When combination antiretroviral therapy is required, provide supporting documentation explaining the medication-management or adherence circumstances when applicable.

    • A significant psychiatric diagnosis causing documented difficulty with adherence; include the specific diagnosis.
    • Homelessness causing difficulty storing larger amounts of medication; documenting homelessness on the PA form is sufficient.
    • Documented adherence difficulty leading to complications, such as low CD4 count resulting in infections or hospitalizations.
    • A child or adolescent member, or a member with documented developmental issues, who lacks adequate support to manage the HIV regimen.
    Denial Risk

    Sunlenca Criteria Not Met

    Sunlenca may be denied when the member does not meet the required clinical eligibility or treatment requirements.

    • Denial conditions include no documented HIV-1 diagnosis, age under 18 years, or no ongoing detectable viremia.
    • Denial conditions include no documented antiretroviral experience with relevant historical or baseline resistance, intolerance, or contraindication; no failure of the current regimen due to resistance, intolerance, or safety concerns; or no required combination therapy.
    • Denial conditions include missing documentation of appropriate dosing or a resistance, adverse-reaction, or contraindication history involving an antiretroviral that is not part of the current regimen.
    Denial Risk

    Trogarzo Criteria or Step-Through Not Met

    Trogarzo may be denied when clinical eligibility, appropriate dosing, combination-therapy, or step-through requirements are not met or documented.

    • Denial conditions include no documented HIV-1 diagnosis, age under 18 years, or no ongoing detectable viremia.
    • Denial conditions include failure to document resistance to one antiretroviral from each of the NRTI, NNRTI, and PI classes, or failure to document combination therapy with at least one other antiretroviral and appropriate dosing.
    • Denial conditions include no inadequate response or adverse reaction to one of Rukobia or Sunlenca, or no contraindication to both Rukobia and Sunlenca.
    Denial Risk

    Insufficient New-Member Transition Documentation

    A new-member request may be denied or delayed when the member's coverage effective date is less than or equal to 90 days and current-treatment records are not submitted.

    • Provide medical records showing current treatment with the requested drug.
    • Treatment obtained as samples or through a manufacturer's patient assistance program does not satisfy this documentation requirement.
    Regimen scopeThe concern must involve the antiretroviral regimen the member is currently receiving.
    Trogarzo three-class resistance
    DefinitionResistance to one antiretroviral medication from each of three antiretroviral classes.
    NRTINucleoside reverse transcriptase inhibitor (NRTI).
    NNRTINon-nucleoside reverse transcriptase inhibitor (NNRTI).
    PIProtease inhibitor (PI).
    Combination agentsCombination antiretroviral agents count toward the three-class resistance requirement.

    The documented history must concern an antiretroviral that is not part of the current regimen.

  4. Member is failing the current antiretroviral regimen due to resistance, intolerance, or safety considerations.

    The documented resistance, adverse reaction, or safety concern must concern the current antiretroviral regimen.

  5. Sunlenca will be used as combination antiretroviral therapy with at least one other antiretroviral.
  6. Member will receive appropriate dosing.
  7. Trogarzo initial therapy

    Trogarzo authorization requires all of the following criteria.

    Trogarzo eligibility

    • Member has a diagnosis of HIV-1 infection.
    • Member is at least 18 years of age.>= 18 years
    • Member has ongoing detectable viremia.e.g., >200 copies/mL
    • Member has resistance to one antiretroviral medication from each of the NRTI, NNRTI, and PI classes.

      Combination agents count toward the three classes.

    • Trogarzo will be used as combination antiretroviral therapy with at least one other antiretroviral.
    • Member will receive appropriate dosing.
    • Rukobia/Sunlenca requirement

      • ONE of

        • Member has an inadequate response to one of Rukobia (fostemsavir) or Sunlenca (lenacapavir).one drug
        • Member has an adverse reaction to one of Rukobia (fostemsavir) or Sunlenca (lenacapavir).one drug
      • Member has a contraindication to both Rukobia (fostemsavir) and Sunlenca (lenacapavir).both drugs